This entry covers evaluation under DC 7704. A clinician establishes the diagnosis separately.
How is it connected to service?
The applicable direct, secondary, aggravation or presumptive route determines the service-connection evidence. Use the evidence guide to distinguish these routes.
Explore service-connection evidence →What do the rating levels describe?
A diagnosis does not automatically establish a percentage. These are the source requirements for evaluating severity; related notes and exceptions still apply.
Compare these levels with the original rating table
Find DC 7704 in the rating schedule
The highlighted row marks this code. Nearby rows provide context and can describe other conditions. Use the full schedule for applicable headings, footnotes and exceptions.
| Rating | |
|---|---|
| Note (2): Evaluate symptomatic chronic lymphocytic leukemia that is at Rai Stage I, II, III, or IV the same as any other leukemia evaluated under this diagnostic code | |
| Note (3): Evaluate residuals of leukemia or leukemia therapy under the appropriate diagnostic code(s). Myeloproliferative Disorders: (Diagnostic Codes 7704, 7718, 7719) | |
| 7704 Polycythemia vera: | |
| Requiring peripheral blood or bone marrow stem-cell transplant or chemotherapy (including myelosuppressants) for the purpose of ameliorating the symptom burden | 100 |
| Requiring phlebotomy 6 or more times per 12-month period or molecularly targeted therapy for the purpose of controlling RBC count | 60 |
| Requiring phlebotomy 4-5 times per 12-month period, or if requiring continuous biologic therapy or myelosuppressive agents, to include interferon, to maintain platelets <200,000 or white blood cells (WBC) <12,000 | 30 |
| Requiring phlebotomy 3 or fewer times per 12-month period or if requiring biologic therapy or interferon on an intermittent basis as needed to maintain all blood values at reference range levels | 10 |
| Note (1): Rate complications such as hypertension, gout, stroke, or thrombotic disease separately | |
| Note (2): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703 | |
Related notes and evaluation rules
Note (1): Rate complications such as hypertension, gout, stroke, or thrombotic disease separately
Note (2): If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703
Note (3): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant; or during the period of treatment with chemotherapy (including myelosuppressants). Six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter
Which evidence addresses the questions?
- The documented diagnosis and applicable diagnostic code.
- Clinical findings and functional effects addressing the applicable source criteria.
- Timing, treatment and connection-to-service evidence for the applicable claim route.
Sources and scope
Guide source check: 2026-11-06. Rating-library snapshot: June 30, 2026. Source coverage is distinct from clinical review. This page does not diagnose, adjudicate a claim, or collect medical records.
Shared reference edition 1.2.4 · source check 2026-11-06. Coverage is stated for each framework and is distinct from clinical review. Rating-source snapshot: 2026-06-30.